Renewed classification of primary iron overload syndromes based on Hep25/FP system

The clinical introduction of hepcidin25 (Hep25) has led to a more detailed understanding of its relationship with ferroportin (FP) and divalent metal transporter1 in primary iron overload syndromes (PIOSs).

Optimi Health Announces Third and Final Tranche of CAD $1,000,000 Secured for Debt Financing | Psychedelic Invest

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation company licensed by Health Canada

November 3, 2023

PharmaKure granted MHRA Clinical Trial Authorisation (CTA) for PK051 for the treatment of mild cognitive impairment due to Alzheimer’s Disease

Clinical Trial Authorisation application granted for combined drug PK051 targeting amyloid deposits associated with Alzheimer’s Disease.

January 4, 2024

Incyte scores soccer star Mia Hamm as new spokesperson to raise awareness of graft-versus-host disease

Incyte is teaming up with a well-known athlete — and longtime bone marrow transplant advocate — for a new awareness campaign. Olympic gold medalist and

August 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.